Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its price target lowered by Maxim Group from $15.00 to $12.00 in a report released on Friday morning, The Fly reports. A number of other equities research analysts also recently weighed in on the stock. UBS Group upgraded shares of Coherus BioSciences from a neutral rating to a […]
MeiraGTx (NASDAQ:MGTX – Get Rating) and Coherus BioSciences (NASDAQ:CHRS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations. Earnings & Valuation This table compares MeiraGTx and Coherus BioSciences’ […]
Coherus BioSciences (NASDAQ:CHRS – Get Rating) and MeiraGTx (NASDAQ:MGTX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends. Valuation & Earnings This table compares Coherus BioSciences and MeiraGTx’s […]
Truist Financial assumed coverage on shares of Coherus BioSciences (NASDAQ:CHRS – Get Rating) in a report published on Monday morning, The Fly reports. The firm issued a buy rating and a $24.00 target price on the biotechnology company’s stock. Several other research firms also recently weighed in on CHRS. HC Wainwright dropped their price target […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective […]